Analysts Set Parabilis Medicines, Inc. (NASDAQ:PBLS) Price Target at $41.67

Parabilis Medicines, Inc. (NASDAQ:PBLS) has earned a consensus recommendation of “Buy” from the six brokerages that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $41.6667.

Several research firms have recently weighed in on PBLS. Lifesci Capital raised shares of Parabilis Medicines to a “strong-buy” rating in a report on Monday, July 6th. Zacks Research upgraded shares of Parabilis Medicines to a “hold” rating in a research note on Tuesday, July 7th. Leerink Partners initiated coverage on Parabilis Medicines in a research note on Monday, July 6th. They issued an “outperform” rating and a $40.00 price target on the stock. Guggenheim initiated coverage on Parabilis Medicines in a research report on Monday, July 6th. They set a “buy” rating and a $40.00 price objective for the company. Finally, Wall Street Zen raised Parabilis Medicines to a “hold” rating in a report on Saturday, June 20th.

Insider Buying and Selling

In other Parabilis Medicines news, major shareholder Guy Levy purchased 500,000 shares of the firm’s stock in a transaction on Thursday, June 11th. The shares were acquired at an average cost of $20.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the insider owned 1,027,000 shares of the company’s stock, valued at approximately $20,540,000. The trade was a 94.88% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Alan Sebulsky purchased 12,500 shares of the company’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average price of $20.00 per share, for a total transaction of $250,000.00. Following the purchase, the director directly owned 12,500 shares in the company, valued at approximately $250,000. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders purchased 530,000 shares of company stock worth $10,723,528.

Parabilis Medicines Stock Performance

PBLS traded up $0.21 during midday trading on Tuesday, hitting $30.57. 664,308 shares of the company traded hands, compared to its average volume of 894,590. Parabilis Medicines has a 52 week low of $24.51 and a 52 week high of $34.47.